Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III VTD vs VCD induction before autologous transplant in newly diagnosed multiple myeloma
2013-003174-27Phase 3Active
- Sponsor
- CHU de Nantes
- Start
- Jun 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bortezomib, thalidomide, cyclophosphamide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by CHU de Nantes. Primary endpoint: VGPR rate after 4 courses of VTD vs VCD. Started Jun 2015; status: active.
02
Drugs
bortezomibthalidomidecyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2013-003174-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003174-27.